Fibroblast Growth Factor 23 in Chronic Respiratory Failure

Launched by ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS · Feb 17, 2022

Keywords

ClinConnect Summary

This clinical trial is exploring how a hormone called Fibroblast Growth Factor 23 (FGF23) behaves in adults with chronic respiratory failure (CRF) who are starting oxygen therapy. Researchers believe that patients with CRF may have higher levels of certain forms of FGF23 due to low oxygen levels in their bodies. This study aims to understand how these levels change with oxygen therapy and how they relate to heart health and other factors like oxygen levels in the blood.

To participate in this trial, individuals must be at least 18 years old and have severe chronic respiratory failure, which means their blood oxygen levels are very low. They should not have received oxygen therapy for at least six weeks before joining the study. Participants will have three visits: one before starting oxygen therapy and two after—at three months and one year. During these visits, researchers will collect health information and perform tests to measure hormone levels and heart function. If you're interested, please discuss this trial with your doctor to see if it might be a good fit for you or your loved one.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patient informed and not opposed to participating in the research
• • Age ≥ 18 years old
• • Severe chronic respiratory failure defined by PaO2 \<60 mmHg, whatever the cause, and justifying the initiation of long-term oxygen therapy
• • Not yet treated or with stopping oxygen therapy for at least 6 weeks
• • Be affiliated with a social security scheme or be a beneficiary of such a scheme
• • Be able to understand the interest and the constraints of the study
• Exclusion Criteria:
• • Exacerbation of respiratory failure in the 6 weeks prior to inclusion
• • Chronic kidney disease defined by a glomerular filtration rate (GFR) estimated by CKD-EPI \<60 mL / min / 1.73m2
• • Anemia at the time of inclusion whatever the cause (sickle cell anemia, thalassemia, hemolytic anemia, chronic iron deficiency, others)
• • Pregnancy
• • Breastfeeding women
• • Simultaneous participation in another therapeutic trial
• • Patient under guardianship or curatorship
• • Patient under medical help from the French government